James W. Green - Aug 23, 2021 Form 4 Insider Report for HARVARD BIOSCIENCE INC (HBIO)

Role: Chief Executive Officer, Director
Signature: /s/ David Sirois, by power of attorney
Stock symbol: HBIO
Transactions as of: Aug 23, 2021
Transactions value $: -$386,364
Form type: 4
Date filed: 8/25/2021, 04:24 PM
Previous filing: Jul 12, 2021
Next filing: Nov 15, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HBIO	Common Stock	Sale	-$386K	-48.2K	-2.25%	$8.02	2.09M	Aug 23, 2021	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was executed in multiple trades at prices ranging from $7.97 to $8.10, inclusive. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2	Includes (a) 218,141 remaining restricted stock units that will vest on June 11, 2022 and 2023, (b) 194,698 restricted stock units that will vest in three equal installments on December 31, 2021, 2022 and 2023, (c) 163,606 remaining restricted stock units that will vest on December 31, 2021, 2022 and 2023, (d) 209,180 remaining restricted stock units that will vest on January 1, 2022 and 2023, (e) 605,035 restricted stock units with performance based vesting conditions tied to relative total shareholder return, and (f) 701,065 shares of common stock beneficially owned by the Reporting Person.

Content

This transaction was executed in multiple trades at prices ranging from $7.97 to $8.10, inclusive. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Includes (a) 218,141 remaining restricted stock units that will vest on June 11, 2022 and 2023, (b) 194,698 restricted stock units that will vest in three equal installments on December 31, 2021, 2022 and 2023, (c) 163,606 remaining restricted stock units that will vest on December 31, 2021, 2022 and 2023, (d) 209,180 remaining restricted stock units that will vest on January 1, 2022 and 2023, (e) 605,035 restricted stock units with performance based vesting conditions tied to relative total shareholder return, and (f) 701,065 shares of common stock beneficially owned by the Reporting Person.